Sysmex in Brief

Strategies

Long-Term Management Targets (2020)

Sysmex’s Ideals for 2020

Positioning

Undisputed Global Leader in Hematology, Hemostasis and Urinalysis (Including Alliances)
We will build the earnings foundation to support further Group growth in the Company’s core businesses.
A Leading Company in the Asian In Vitro Diagnostic (IVD) Market
We will leverage our geographic advantage to build a solid position in the Asian market in growth fields, including non-hematology field.
A Unique and Competitive Player in the Immunology Field
We will harness unique strengths that other companies cannot emulate and drive Group growth over the medium term.
A Leading Global Player Making a Contribution to Personalized Healthcare
By augmenting value in testing (diagnostics) based on leading-edge technologies, we will accelerate Group growth and establish our global position.
An Attractive Company Providing Value and Confidence
We aim to become a highly attractive company to diverse stakeholders that offers value and reassurance.
One Sysmex Carrying Out High-Speed Management
Through optimal teamwork throughout the Group, we aim to be a corporate entity that conducts highly efficient and swift management.

Mid-Term Management Plan (Fiscal Years Ending March 31, 2016 to 2018)

  • Reinforce growth and profitability
  • Invest in growth
  • Promote transformation

Financial targets (Fiscal year ending March 31, 2018)

Net Sales ¥300.0 billion
(CAGR* = 10.7%)
Operating
income
¥63.0 billion
(CAGR* = 12.4%)
(Operating margin of 21.0%)
ROE 18.0%
Operating
cash flow
¥50.0 billion
Free
cash flow
¥20.0 billion

Exchange rate assumptions: 1USD=¥115, 1EUR=¥130, 1CNY=¥18.5

*CAGR (compound annual growth rate): For fiscal years ending March 31, 2015 to 2018

Initiatives to Achieve Positioning

Reinforce growth and profitability

(1) Undisputed Global Leader in Hematology, Hemostasis and Urinalysis (Including Alliances)
  • Accelerate introduction of the XN-Series and make full-fledged launch of the XN-L-Series in emerging markets
  • Expand global offerings of clinical FCM products employing technology possessed by Partec
  • Expand global sales of the CS-Series hemostasis analyzer, including in the United States, and make use of alliances
  • Augment our product lineup in the urinalysis field and enhance global sales and support services
(2) A leading Company in the Asian In Vitro Diagnostics (IVD) Market
  • In addition to the hematology, hemostasis and urinalysis fields, reinforce comprehensive proposals, including in the immunochemistry field
  • Develop products and strengthen our sales and support networks tailored to regional needs
  • Promote scientific support activities to increase the level of IVD testing

Invest in growth

(3) A Unique and Competitive Player in the Immunology Field
  • Accelerate introduction of the HISCL-Series, which features high sensitivity, high speed and unique parameters.
    Hepatic fibrosis marker (M2BPGi), atopic dermatitis marker (TARC), etc.
  • Enhance support service structure by leveraging online support capabilities
(4) A Leading Global Player Making a Contribution to Personalized Healthcare
  • Increase the types of cancer to which the OSNA method is applied, and expand sales region globally
  • Leverage Inostics technology (BEAMing*1) to expand the gene testing business
  • Reinforce R&D capabilities to realize liquid biopsy*2
  • *1 An acronym for “Bead, Emulsion, Amplification, and Magnetics,” this gene analysis method combines digital PCR (ultrahigh-sensitivity PCR) and flow cytometry technologies.
  • *2 Detection of cancer or other diseases by testing blood or other bodily fluids.

Promote transformation

(5) An Attractive Company Providing Value and Confidence
  • Enhance the corporate communication function to facilitate interaction with diverse stakeholders
  • Augment customer satisfaction by reinforcing our scientific and support functions
(6) One Sysmex Carrying Out High-Speed Management
  • Recruit globally effective human resources and make use of the Global Communication Center to cultivate human resources
  • Strengthen risk management and reinforce Group management foundations by making use of ICT